Levofloxacin Kabi

Levofloxacin, the active ingredient in Levofloxacin Kabi, is a fluoroquinolone presented as a sterile powder for reconstitution for intravenous use. It treats a broad range of serious bacterial infections in adult patients, including respiratory, urinary, and intra‑abdominal infections. GNH USA supplies Levofloxacin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Levofloxacin is indicated for several serious bacterial infections, acting primarily on Gram‑negative and Gram‑positive pathogens.

- Community‑Acquired Bacterial Pneumonia: effective in achieving clinical cure and microbiological eradication. - Hospital‑Acquired or Ventilator‑Associated Pneumonia: provides coverage against common nosocomial respiratory pathogens. - Complicated Urinary Tract Infections (including pyelonephritis): facilitates bacterial clearance and symptom resolution. - Intra‑Abdominal Infections (post‑operative or peritonitis): contributes to infection control when combined with appropriate anaerobic coverage. - Skin and Soft Tissue Infections: helps achieve healing and prevents spread of infection.

Levofloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Elevated liver enzymes

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation and cardiac arrhythmias - Clostridioides difficile‑associated diarrhea - Severe allergic reactions, including anaphylaxis - Hepatic failure or severe liver injury - Seizures, especially in patients with CNS disorders

Before initiating therapy, clinicians should consider several safety measures.

- Renal Function Assessment: adjust dosing in patients with impaired clearance. - Tendon Monitoring: discontinue if tendon pain or inflammation occurs. - QT Prolongation Risk: avoid in patients with known prolonged QT or concurrent QT‑prolonging drugs. - Pregnancy Consideration: use only if benefits outweigh potential risks, as safety data are limited. - Concomitant Medication Review: evaluate for interactions that may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levofloxacin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce levofloxacin absorption. - Warfarin: may increase INR and bleeding risk. - Theophylline: increased plasma concentrations leading to toxicity. - Cyclosporine: elevated levofloxacin levels may cause adverse effects.

Moderate Interactions (Monitor Closely): - Corticosteroids: heightened risk of tendon rupture. - Diabetic agents (e.g., insulin, sulfonylureas): potential for hypoglycemia. - Other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): monitor cardiac rhythm. - NSAIDs: may increase risk of central nervous system stimulation.